These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25401784)

  • 21. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.
    Ohtake A; Sato S; Sasamata M; Miyata K
    J Pharmacol Sci; 2010; 112(2):135-41. PubMed ID: 20134114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
    Staskin DR; Te AE
    BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.
    Kaplan SA; Goldfischer ER; Steers WD; Gittelman M; Andoh M; Forero-Schwanhaeuser S
    Aging Male; 2010 Jun; 13(2):100-7. PubMed ID: 20001469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms.
    Liu M; Wang J; Yang Y; An R; Wen J; Guan Z; Zheng S; Wang D; Song B; Liao L; Guo H; Xiao J; Sun Y; Shen Z; Kong C; He D; Huang Y; Wang X; Zhang X; Li H; Huang J; Zhao X; Zeng P; Song X; Ye Z
    Chin Med J (Engl); 2014; 127(2):261-5. PubMed ID: 24438613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.
    Mattiasson A; Masala A; Morton R; Bolodeoku J;
    BJU Int; 2010 Apr; 105(8):1126-35. PubMed ID: 19818077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes.
    Mallett V; Burks D; Garely AD; Smith N
    Curr Med Res Opin; 2007 Apr; 23(4):821-31. PubMed ID: 17407639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solifenacin significantly improves all symptoms of overactive bladder syndrome.
    Chapple CR; Cardozo L; Steers WD; Govier FE
    Int J Clin Pract; 2006 Aug; 60(8):959-66. PubMed ID: 16893438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.
    Brunton S; Kuritzky L
    Curr Med Res Opin; 2005 Jan; 21(1):71-80. PubMed ID: 15881477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin.
    Sand PK; Steers WD; Dmochowski R; Andoh M; Forero-Schwanhaeuser S
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Jun; 20(6):667-75. PubMed ID: 19434385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, observational study to assess the association between dry mouth and solifenacin treatment in patients with overactive bladder syndrome.
    Park J; Chun JY; Kim JH; Cheon SY; Song M; Choo MS; Lee KS; Oh SJ; Kim JC; Choi JB; Seo JT; Cho SY
    Int Urol Nephrol; 2015 Feb; 47(2):235-42. PubMed ID: 25503446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
    Zinner N; Noe L; Rasouliyan L; Marshall T; Seifeldin R
    Curr Med Res Opin; 2008 Jun; 24(6):1583-91. PubMed ID: 18423103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
    Oresković S; But I; Banović M; Goldstajn MS
    Coll Antropol; 2012 Mar; 36(1):243-8. PubMed ID: 22816227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q).
    Gotoh M; Kobayashi T; Sogabe K
    Int J Urol; 2014 May; 21(5):505-11. PubMed ID: 24304092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape--is it effective?
    Serati M; Braga A; Sorice P; Siesto G; Salvatore S; Ghezzi F
    J Urol; 2014 May; 191(5):1322-6. PubMed ID: 24148761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.